Alvaro Gonzalez, PhD


Full Professor
Department of Biochemistry
Faculty of Science
University Clinic of Navarra
Avenida Pío XII 36
Pamplona 31008, Spain

Biography

EDUCATION QUALIFICATIONS

• (1987) Pharmacy: University of Santiago de Compostela, Spain
• (July 1991) PhD degree, Departments of Biochemistry, University of Navarra, Spain
• (1997) Docent in Biochemistry, University of Navarra, Spain
• (1998-1991) Resident in Clinical Chemistry: University Clinic of Navarra

PROFESSIONAL EXPERIENCE

• Full Professor of Clinica Biochemistry, Faculty of Science, University of Navarra, Spain

Research Interest

His research interests include: Immunotolerance and Cancer, Biomarkers of cancer.

Scientific Activities

HONOR

• Director of the laboratory Clinical Chemistry. University Clinic of Navarra. Spain

Publications

SELECTED PEER-REVIEWED ARTICLES IN LAST 5 YEARS

1. González A., Alegre E, Torres MI, et al. Evaluation of HLA-G5 plasmatic levels during pregnancy and relationship with the 14-bp polymorphism. Am J Reprod Immunol. 2010; 64: 367-374. doi: 10.1111/j.1600-0897.2010.00855.x
2. Alegre E, Howangyin KY, Favier B, et al. Membrane redistributions through multi-intercellular exchanges and serial trogocytosis. Cell Res. 2010; 20: 1239-1251. doi: 10.1038/cr.2010.136
3. Suarez N, Alfaro C, Dubrot J, et al. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer. 2011; 129: 374-386. doi: 10.1002/ijc.25681
4. Alfaro C, Suárez N, Martínez-Forero I, et al. Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS One. 2011; 14: e17922. doi: 10.1371/journal.pone.0017922
5. González A, Alegre E, Arroyo A, LeMaoult J, Echeveste JI. Identification of circulating non-classical human leukocyte antigen (HLA)-G-like molecules in exudates. Clin Chem. 2011; 57: 1013-1022. doi: 10.1373/clinchem.2010.159673
6. Díaz-Lagares A, Alegre E, Arroyo A, et al. Evaluation of multiple serum markers in advanced melanoma . Tumour Biol. 2011; 32: 1155-1161. doi: 10.1007/s13277-011-0218-x
7. Alfaro C, Perez-Gracia JL, Suarez N, et al. Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients. J Immunol. 2011; 187: 6130-6142. doi: 10.4049/jimmunol.1102209
8. Alfaro C, Suarez N, Oñate C, et al. Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes. PLoS One. 2011; 6: e29300. doi: 10.1371/journal.pone.0029300
9. González A, Rebmann V, LeMaoult J, Horn PA, Carosella ED, Alegre E. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci. 2012; 49: 63-84. doi: 10.3109/10408363.2012.677947
10. Alegre E, Rebmann V, Lemaoult J, et al. In vivo identification of an HLA-G complex as ubiquitinated protein circulating in exosomes. Eur J Immunol. 2013; 43: 1933-1939. doi: 10.1002/eji.201343318
11. Prior C, Perez-Gracia, JL, Garcia-Donas J, et al. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. Plos One. 2014; 9: e86263
12. Alegre E, Sanmamed M, Rodríguez C, Carranza O, Martín-Algarra S, González A. Study of circulating miRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med. 2014; 138: 828-832. doi: 10.5858/arpa.2013-0134-OA
13. Manterola L, Guruceaga E, Pérez-Larraya JG, et al. A sncRNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro-Oncology. 2014: 16: 520-527.
14. Sanmamed MF, Fernández-Landázuri S, Rodriguez C, et al. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clin Chim Acta. 2014; 429: 168-174.
15. Alegre E, Rizzo R, Bortolotti D, Fernandez-Landazuri S, Fainardi E, González A. Some basic aspects of HLA-G biology. J Immunol Res. 2014; 2014: 657625.
16. Sanmamed MF, Carranza-Rua O, Alfaro C, et al. Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. Clin Cancer Res. 2014; 20: 5697-5707. doi: 10.1158/1078-0432.CCR-13-3203
17. Sanmamed MF, Fernández-Landázuri S, Rodríguez C et al. Quantitative cell-free circulating BRAFV600E mutation analysis using droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015; 61: 297-304. doi: 10.1373/clinchem.2014.230235